Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.37 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601953 | 0.86 | ABCB1 (0.43) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL3602288 | 0.81 | NPC1 (0.41) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL3599146 | 0.80 | KCNE1 (0.40) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL3599142 | 0.80 | KCNE1 (0.40) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL2011765 | 0.77 | ABCB1 (0.46) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL13199633 | 0.74 | ABCB1 (0.44) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL13199634 | 0.74 | ABCB1 (0.44) | L3MBTL1ABCB1CYP3A4ALOX15KCNE1 | |
| SCHEMBL12580677 | 0.73 | ABCB1 (0.41) | ABCB1CYP3A4ALOX15KCNE1KCNQ1 | |
| SCHEMBL2012197 | 0.72 | ABCB1 (0.42) | ABCB1CYP3A4ALOX15KCNE1KCNQ1 | |
| SCHEMBL13199529 | 0.72 | ABCB1 (0.43) | ABCB1CYP3A4ALOX15KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | L3MBTL1 1562/4885ABCB1 647/4885CYP3A4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.